<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36941341</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2399-3642</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Communications biology</Title><ISOAbbreviation>Commun Biol</ISOAbbreviation></Journal><ArticleTitle>Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.</ArticleTitle><Pagination><StartPage>295</StartPage><MedlinePgn>295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42003-023-04667-8</ELocationID><Abstract><AbstractText>Prolactin (PRL) is elevated in B-cell-mediated lymphoproliferative diseases and promotes B-cell survival. Whether PRL or PRL receptors drive the evolution of B-cell malignancies is unknown. We measure changes in B cells after knocking down the pro-proliferative, anti-apoptotic long isoform of the PRL receptor (LFPRLR) in vivo in systemic lupus erythematosus (SLE)- and B-cell lymphoma-prone mouse models, and the long plus intermediate isoforms (LF/IFPRLR) in human B-cell malignancies. To knockdown LF/IFPRLRs without suppressing expression of the counteractive short PRLR isoforms (SFPRLRs), we employ splice-modulating DNA oligomers. In SLE-prone mice, LFPRLR knockdown reduces numbers and proliferation of pathogenic B-cell subsets and lowers the risk of B-cell transformation by downregulating expression of activation-induced cytidine deaminase. LFPRLR knockdown in lymphoma-prone mice reduces B-cell numbers and their expression of BCL2 and TCL1. In overt human B-cell malignancies, LF/IFPRLR knockdown reduces B-cell viability and their MYC and BCL2 expression. Unlike normal B cells, human B-cell malignancies secrete autocrine PRL and often express no SFPRLRs. Neutralization of secreted PRL reduces the viability of B-cell malignancies. Knockdown of LF/IFPRLR reduces the growth of human B-cell malignancies in vitro and in vivo. Thus, LF/IFPRLR knockdown is a highly specific approach to block the evolution of B-cell neoplasms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taghi Khani</LastName><ForeName>Adeleh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4978-593X</Identifier><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez Ortiz</LastName><ForeName>Ashly</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radecki</LastName><ForeName>Kelly C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, 92521, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aramburo</LastName><ForeName>Soraya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sung June</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zunsong</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-3167-7148</Identifier><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damirchi</LastName><ForeName>Behzad</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenson</LastName><ForeName>Mary Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, 92521, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA, 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zhaohui</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1581-1327</Identifier><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stohl</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8272-7873</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4182-587X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meffre</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;schen</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6064-8613</Identifier><AffiliationInfo><Affiliation>Center of Molecular and Cellular Oncology, Yale School of Medicine, 300 George Street, 06520, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forman</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-2803-4152</Identifier><AffiliationInfo><Affiliation>Department of Hematology &amp; Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, 91010, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koff</LastName><ForeName>Jean L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-4414-0489</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Ameae M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-7614-7450</Identifier><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, 92521, USA. ameae.walker@ucr.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Srividya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3459-7488</Identifier><AffiliationInfo><Affiliation>Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, 91016, USA. sswaminathan@coh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA. sswaminathan@coh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA107399</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA033572</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Biol</MedlineTA><NlmUniqueID>101719179</NlmUniqueID><ISSNLinking>2399-3642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011981">Receptors, Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-62-4</RegistryNumber><NameOfSubstance UI="D011388">Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011981" MajorTopicYN="N">Receptors, Prolactin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016393" MajorTopicYN="Y">Lymphoma, B-Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.M.W. and S.S. declare the following competing interests: The work described in this study is covered under a pending US patent application (Inventors: A.M.W. and S.S.). All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36941341</ArticleId><ArticleId IdType="pmc">PMC10027679</ArticleId><ArticleId IdType="doi">10.1038/s42003-023-04667-8</ArticleId><ArticleId IdType="pii">10.1038/s42003-023-04667-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sinha R, Nastoupil L, Flowers CR. Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. Blood Lymphat Cancer. 2012;2012:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606548</ArticleId><ArticleId IdType="pubmed">23532092</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin. Proc. 2016;91:1645&#x2013;1666. doi: 10.1016/j.mayocp.2016.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2016.09.010</ArticleId><ArticleId IdType="pubmed">27814839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, et al. Cancer risk in childhood-onset systemic lupus. Arthritis Res. Ther. 2013;15:1&#x2013;4. doi: 10.1186/ar4388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4388</ArticleId><ArticleId IdType="pmc">PMC3978586</ArticleId><ArticleId IdType="pubmed">24267155</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann. Rheum. Dis. 2014;73:138&#x2013;142. doi: 10.1136/annrheumdis-2012-202099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202099</ArticleId><ArticleId IdType="pmc">PMC3855611</ArticleId><ArticleId IdType="pubmed">23303389</ArticleId></ArticleIdList></Reference><Reference><Citation>Koff JL, Flowers CR. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev. Hematol. 2016;9:553&#x2013;561. doi: 10.1080/17474086.2016.1180972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2016.1180972</ArticleId><ArticleId IdType="pmc">PMC5050045</ArticleId><ArticleId IdType="pubmed">27098121</ArticleId></ArticleIdList></Reference><Reference><Citation>White CA, et al. AID dysregulation in lupus-prone MRL/Fas lpr/lpr mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4. Autoimmunity. 2011;44:585&#x2013;598. doi: 10.3109/08916934.2011.577128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2011.577128</ArticleId><ArticleId IdType="pmc">PMC3762595</ArticleId><ArticleId IdType="pubmed">21585311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best. Pract. Res. Clin. Haematol. 2011;24:147&#x2013;163. doi: 10.1016/j.beha.2011.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2011.02.006</ArticleId><ArticleId IdType="pmc">PMC3112479</ArticleId><ArticleId IdType="pubmed">21658615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. 2002;99:8242&#x2013;8247. doi: 10.1073/pnas.112218799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.112218799</ArticleId><ArticleId IdType="pmc">PMC123052</ArticleId><ArticleId IdType="pubmed">12048236</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 2015;16:766&#x2013;774. doi: 10.1038/ni.3160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3160</ArticleId><ArticleId IdType="pmc">PMC4475638</ArticleId><ArticleId IdType="pubmed">25985233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard V, Young J, Binart N. Prolactin&#x2014;a pleiotropic factor in health and disease. Nat. Rev. Endocrinol. 2019;15:356&#x2013;365. doi: 10.1038/s41574-019-0194-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-019-0194-6</ArticleId><ArticleId IdType="pubmed">30899100</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramicheva P, Smirnova O. Prolactin receptor isoforms as the basis of tissue-specific action of prolactin in the norm and pathology. Biochem. (Mosc.) 2019;84:329&#x2013;345. doi: 10.1134/S0006297919040011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297919040011</ArticleId><ArticleId IdType="pubmed">31228925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab. 2002;13:245&#x2013;250. doi: 10.1016/S1043-2760(02)00603-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1043-2760(02)00603-3</ArticleId><ArticleId IdType="pubmed">12128285</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol. Lett. 2005;101:123&#x2013;143. doi: 10.1016/j.imlet.2005.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2005.05.014</ArticleId><ArticleId IdType="pubmed">16061292</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin. Rev. Allergy Immunol. 2011;40:8&#x2013;15. doi: 10.1007/s12016-009-8182-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-009-8182-6</ArticleId><ArticleId IdType="pubmed">19937157</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker SE, Allen SH, Hoffman RW, McMurray RW. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus. 1995;4:3&#x2013;9. doi: 10.1177/096120339500400102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339500400102</ArticleId><ArticleId IdType="pubmed">7767336</ArticleId></ArticleIdList></Reference><Reference><Citation>Berczi, I., Nagy, E, De Toledo, S., Matusik, R. &amp; Friesen, H. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J. Immunol. 146, 2201&#x2013;2206 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2005393</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Caceres MA, et al. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene. 2004;23:7378&#x2013;7390. doi: 10.1038/sj.onc.1208002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208002</ArticleId><ArticleId IdType="pubmed">15286700</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Fern&#xe1;ndez R, et al. Prolactin rescues immature B cells from apoptosis-induced BCR-aggregation through STAT3, Bcl2a1a, Bcl2l2, and Birc5 in lupus-prone MRL/lpr mice. Cells. 2021;10:316. doi: 10.3390/cells10020316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020316</ArticleId><ArticleId IdType="pmc">PMC7913714</ArticleId><ArticleId IdType="pubmed">33557010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochendoerfer S, Krishnan N, Buckley D, Buckley A. Prolactin regulation of Bcl-2 family members: increased expression of bcl-xL but not mcl-1 or bad in Nb2-T cells. J. Endocrinol. 2003;178:265&#x2013;274. doi: 10.1677/joe.0.1780265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe.0.1780265</ArticleId><ArticleId IdType="pubmed">12904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, et al. Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes. Proc. Natl Acad. Sci. 1995;92:3278&#x2013;3282. doi: 10.1073/pnas.92.8.3278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3278</ArticleId><ArticleId IdType="pmc">PMC42149</ArticleId><ArticleId IdType="pubmed">7724552</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott J, Hovey R, Koduri S, Vonderhaar B. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J. Mol. Endocrinol. 2003;30:31&#x2013;48. doi: 10.1677/jme.0.0300031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/jme.0.0300031</ArticleId><ArticleId IdType="pubmed">12580759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormandy CJ, Binart N, Helloco C, Kelly PA. Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3&#x2032;-exon splicing. DNA Cell Biol. 1998;17:761&#x2013;770. doi: 10.1089/dna.1998.17.761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.1998.17.761</ArticleId><ArticleId IdType="pubmed">9778035</ArticleId></ArticleIdList></Reference><Reference><Citation>Grible JM, et al. The human intermediate prolactin receptor is a mammary proto-oncogene. NPJ Breast Cancer. 2021;7:1&#x2013;11. doi: 10.1038/s41523-021-00243-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41523-021-00243-7</ArticleId><ArticleId IdType="pmc">PMC7997966</ArticleId><ArticleId IdType="pubmed">33772010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavarthapu, R. &amp; Dufau, M. L. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. Front. Endocrinol.13, 949396 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9520000</ArticleId><ArticleId IdType="pubmed">36187116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D, Walker AM. Short form 1b human prolactin receptor down-regulates expression of the long form. J. Mol. Endocrinol. 2010;44:187. doi: 10.1677/JME-09-0101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/JME-09-0101</ArticleId><ArticleId IdType="pubmed">19906835</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Coppenolle F, et al. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation. Biochem. J. 2004;377:569&#x2013;578. doi: 10.1042/bj20030859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj20030859</ArticleId><ArticleId IdType="pmc">PMC1223902</ArticleId><ArticleId IdType="pubmed">14565846</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews BS, et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 1978;148:1198&#x2013;1215. doi: 10.1084/jem.148.5.1198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.148.5.1198</ArticleId><ArticleId IdType="pmc">PMC2185049</ArticleId><ArticleId IdType="pubmed">309911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer KK, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc. Natl Acad. Sci. 2002;99:14392&#x2013;14397. doi: 10.1073/pnas.212410199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.212410199</ArticleId><ArticleId IdType="pmc">PMC137894</ArticleId><ArticleId IdType="pubmed">12381789</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonezawa T, et al. Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer. Cancer Lett. 2015;366:84&#x2013;92. doi: 10.1016/j.canlet.2015.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.06.010</ArticleId><ArticleId IdType="pubmed">26095602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K-HE, et al. Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor. Transl. Oncol. 2021;14:101195. doi: 10.1016/j.tranon.2021.101195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2021.101195</ArticleId><ArticleId IdType="pmc">PMC8358703</ArticleId><ArticleId IdType="pubmed">34375938</ArticleId></ArticleIdList></Reference><Reference><Citation>Rys RN, Venkataraman M, Zeng J, Mann KK, Johnson NJB. Fas Mutations in Non-Hodgkin&#x2019;s Lymphoma (NHL): implications for disease progression and therapeutic resistance. Blood. 2019;134:1520. doi: 10.1182/blood-2019-130602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2019-130602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf8;nb&#xe6;k K, et al. Somatic Fas mutations in non-Hodgkin&#x2019;s lymphoma: association with extranodal disease and autoimmunity. Blood. 1998;92:3018&#x2013;3024. doi: 10.1182/blood.V92.9.3018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V92.9.3018</ArticleId><ArticleId IdType="pubmed">9787134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkiel S, Barlev AN, Atisha-Fregoso Y, Suurmond J, Diamond B. Plasma cell differentiation pathways in systemic lupus erythematosus. Front. Immunol. 2018;9:427. doi: 10.3389/fimmu.2018.00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00427</ArticleId><ArticleId IdType="pmc">PMC5845388</ArticleId><ArticleId IdType="pubmed">29556239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 2014;10:365&#x2013;373. doi: 10.1038/nrrheum.2014.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2014.33</ArticleId><ArticleId IdType="pubmed">24614588</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekeredjian-Ding IB, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 2005;174:4043&#x2013;4050. doi: 10.4049/jimmunol.174.7.4043.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.7.4043</ArticleId><ArticleId IdType="pubmed">15778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti A, Qiao X, He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol. Cell Biol. 2005;83:554&#x2013;562. doi: 10.1111/j.1440-1711.2005.01389.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1711.2005.01389.x</ArticleId><ArticleId IdType="pubmed">16174107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding C, et al. Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. J. Immunol. 2009;183:7140&#x2013;7149. doi: 10.4049/jimmunol.0901175.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901175</ArticleId><ArticleId IdType="pmc">PMC3351849</ArticleId><ArticleId IdType="pubmed">19890051</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Dorta-Estremera S, Yao Y, Shen N, Cao W. Predominant role of plasmacytoid dendritic cells in stimulating systemic autoimmunity. Front. Immunol. 2015;6:526. doi: 10.3389/fimmu.2015.00526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00526</ArticleId><ArticleId IdType="pmc">PMC4601279</ArticleId><ArticleId IdType="pubmed">26528288</ArticleId></ArticleIdList></Reference><Reference><Citation>William J, Euler C, Christensen S, Shlomchik MJJS. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science. 2002;297:2066&#x2013;2070. doi: 10.1126/science.1073924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1073924</ArticleId><ArticleId IdType="pubmed">12242446</ArticleId></ArticleIdList></Reference><Reference><Citation>William J, Euler C, Shlomchik MJ. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J. Immunol. 2005;174:6879&#x2013;6887. doi: 10.4049/jimmunol.174.11.6879.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.6879</ArticleId><ArticleId IdType="pubmed">15905530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xia Y. Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Front. Immunol. 2019;10:1667. doi: 10.3389/fimmu.2019.01667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01667</ArticleId><ArticleId IdType="pmc">PMC6650533</ArticleId><ArticleId IdType="pubmed">31379858</ArticleId></ArticleIdList></Reference><Reference><Citation>Carre&#xf3;n-Talavera, R. et al. Prolactin promotes proliferation of germinal center B cells, formation of plasma cells, and elevated levels of IgG3 anti-dsDNA autoantibodies. Front. Immunol.13, 10.3389/fimmu.2022.1017115 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9641231</ArticleId><ArticleId IdType="pubmed">36389691</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonnell TJ, et al. Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol. Cell Biol. 1990;10:1901&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC360535</ArticleId><ArticleId IdType="pubmed">2183011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993;81:2475&#x2013;2475. doi: 10.1182/blood.V81.10.2475.2475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V81.10.2475.2475</ArticleId><ArticleId IdType="pubmed">8490163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardemann H, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374&#x2013;1377. doi: 10.1126/science.1086907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086907</ArticleId><ArticleId IdType="pubmed">12920303</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J. Immunol. 1997;158:235&#x2013;246. doi: 10.4049/jimmunol.158.1.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.158.1.235</ArticleId><ArticleId IdType="pubmed">8977195</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini SS, Allore B, Jacobs RM, Kaushik A. Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Eur. J. Immunol. 1999;29:2420&#x2013;2426. doi: 10.1002/(SICI)1521-4141(199908)29:08&lt;2420::AID-IMMU2420&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199908)29:08&lt;2420::AID-IMMU2420&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">10458755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AG, et al. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008;135:1130&#x2013;1142. doi: 10.1016/j.cell.2008.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.10.035</ArticleId><ArticleId IdType="pmc">PMC2642632</ArticleId><ArticleId IdType="pubmed">19070581</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu M, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553&#x2013;563. doi: 10.1016/S0092-8674(00)00078-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)00078-7</ArticleId><ArticleId IdType="pubmed">11007474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai T, et al. Estrogen receptors bind to and activate the HOXC4/HoxC4 promoter to potentiate HoxC4-mediated activation-induced cytosine deaminase induction, immunoglobulin class switch DNA recombination, and somatic hypermutation. J. Biol. Chem. 2010;285:37797&#x2013;37810. doi: 10.1074/jbc.M110.169086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.169086</ArticleId><ArticleId IdType="pmc">PMC2988384</ArticleId><ArticleId IdType="pubmed">20855884</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino RN, Ding L, Veis DJ, Korsmeyer SJ, Nu&#xf1;ez G. Developmental regulation of the Bcl&#x2010;2 protein and susceptibility to cell death in B lymphocytes. EMBO J. 1994;13:683&#x2013;691. doi: 10.1002/j.1460-2075.1994.tb06307.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1994.tb06307.x</ArticleId><ArticleId IdType="pmc">PMC394859</ArticleId><ArticleId IdType="pubmed">8313913</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan RA, et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science. 2008;321:696&#x2013;699. doi: 10.1126/science.1157533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1157533</ArticleId><ArticleId IdType="pubmed">18566249</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmond DG. Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs. Curr. Opin. Immunol. 1991;3:179&#x2013;185. doi: 10.1016/0952-7915(91)90047-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0952-7915(91)90047-5</ArticleId><ArticleId IdType="pubmed">2069745</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobe N, R&#xfc;hle H, Eckelmann G. Hyperprolactin&#xe4;mie bei malignen Lymphomen. DMW-Dtsch. Med. Wochenschr. 1990;115:1825&#x2013;1827. doi: 10.1055/s-2008-1065232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1065232</ArticleId><ArticleId IdType="pubmed">2245764</ArticleId></ArticleIdList></Reference><Reference><Citation>Matera L, et al. Expression of prolactin and prolactin receptors by non&#x2010;Hodgkin&#x2019;s lymphoma cells. Int. J. Cancer. 2000;85:124&#x2013;130. doi: 10.1002/(SICI)1097-0215(20000101)85:1&lt;124::AID-IJC22&gt;3.0.CO;2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(20000101)85:1&lt;124::AID-IJC22&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">10585595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel M, et al. A biologic definition of Burkitt&#x2019;s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006;354:2419&#x2013;2430. doi: 10.1056/NEJMoa055351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa055351</ArticleId><ArticleId IdType="pubmed">16760442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz G, et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008;359:2313&#x2013;2323. doi: 10.1056/NEJMoa0802885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802885</ArticleId><ArticleId IdType="pmc">PMC9103713</ArticleId><ArticleId IdType="pubmed">19038878</ArticleId></ArticleIdList></Reference><Reference><Citation>Jais J-P, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008;22:1917&#x2013;1924. doi: 10.1038/leu.2008.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2008.188</ArticleId><ArticleId IdType="pmc">PMC2675107</ArticleId><ArticleId IdType="pubmed">18615101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat. Genet. 2019;51:296&#x2013;307. doi: 10.1038/s41588-018-0315-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0315-5</ArticleId><ArticleId IdType="pmc">PMC6525306</ArticleId><ArticleId IdType="pubmed">30643249</ArticleId></ArticleIdList></Reference><Reference><Citation>Utama FE, et al. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology. 2009;150:1782&#x2013;1790. doi: 10.1210/en.2008-1057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2008-1057</ArticleId><ArticleId IdType="pmc">PMC2659276</ArticleId><ArticleId IdType="pubmed">19022890</ArticleId></ArticleIdList></Reference><Reference><Citation>De Kesel, J., Fijalkowski, I., Taylor, J. &amp; Ntziachristos, P. Splicing dysregulation in human hematologic malignancies: beyond splicing mutations. Trends Immunol.43, 674&#x2013;686 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35850914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairlie WD, Lee EF. Co-operativity between MYC and BCL-2 pro-survival proteins in cancer. Int. J. Mol. Sci. 2021;22:2841. doi: 10.3390/ijms22062841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22062841</ArticleId><ArticleId IdType="pmc">PMC8000576</ArticleId><ArticleId IdType="pubmed">33799592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tessier-Cloutier B, et al. Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. Lupus Sci. Med. 2019;6:e000324. doi: 10.1136/lupus-2019-000324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000324</ArticleId><ArticleId IdType="pmc">PMC6541753</ArticleId><ArticleId IdType="pubmed">31205728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. J. Am. Soc. Hematol. 2013;121:4021&#x2013;4031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709650</ArticleId><ArticleId IdType="pubmed">23449635</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal M, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod. Pathol. 2009;22:206&#x2013;215. doi: 10.1038/modpathol.2008.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2008.148</ArticleId><ArticleId IdType="pubmed">18820675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramuz O, et al. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int. J. Oncol. 2005;26:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">15586235</ArticleId></ArticleIdList></Reference><Reference><Citation>Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood J. Am. Soc. Hematol. 2015;126:454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624440</ArticleId><ArticleId IdType="pubmed">26065657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the&#x2019;undruggable&#x2019;cancer targets. Nat. Rev. Cancer. 2017;17:502&#x2013;508. doi: 10.1038/nrc.2017.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.36</ArticleId><ArticleId IdType="pmc">PMC5945194</ArticleId><ArticleId IdType="pubmed">28643779</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker S. Treatment of systemic lupus erythematosus with bromocriptine. Lupus. 2001;10:197&#x2013;202. doi: 10.1191/096120301666625458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301666625458</ArticleId><ArticleId IdType="pubmed">11315352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano M, Kelly PA. Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J. Biol. Chem. 1994;269:13337&#x2013;13345. doi: 10.1016/S0021-9258(17)36838-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)36838-2</ArticleId><ArticleId IdType="pubmed">8175764</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat. Med. 2013;19:1014&#x2013;1022. doi: 10.1038/nm.3247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3247</ArticleId><ArticleId IdType="pmc">PMC3954721</ArticleId><ArticleId IdType="pubmed">23852341</ArticleId></ArticleIdList></Reference><Reference><Citation>Duy C, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 2010;207:1209&#x2013;1221. doi: 10.1084/jem.20091299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091299</ArticleId><ArticleId IdType="pmc">PMC2882829</ArticleId><ArticleId IdType="pubmed">20498019</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster MH, MacDonald M, Barrett KJ, Madaio MP. VH gene analysis of spontaneously activated B cells in adult MRL-lpr/lpr mice. J558 bias is not limited to classic lupus autoantibodies. J. Immunol. 1991;147:1504&#x2013;1511. doi: 10.4049/jimmunol.147.5.1504.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.147.5.1504</ArticleId><ArticleId IdType="pubmed">1908876</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders, S., Reyes, A. &amp; Huber, W. Detecting differential usage of exons from RNA-seq data. Genome Res. 22, 2008&#x2013;2017 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460195</ArticleId><ArticleId IdType="pubmed">22722343</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1&#x2013;21. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>